Full-Time

Analyst – Level 2

Operations

Posted on 12/13/2025

PCI Pharma Services

PCI Pharma Services

1-10 employees

Pharmaceutical packaging and contract services

No salary listed

Cardiff, UK

In Person

Category
Operations & Logistics (1)
Requirements
  • A degree in a scientific subject as a minimum (preferably Chemistry)
  • Previous laboratory and analytical experience essential (minimum 1 year), preferably in a pharmaceutical environment
  • GMP Skill Level 1 is essential for this role.
  • The job holder is responsible for adhering to PCI SOPs, Health & Safety, GMP and other regulatory guidelines.
Responsibilities
  • To perform routine laboratory procedures right first time with minimal personal OOS results and if relevant and instructed to do so, to assist others within the team.
  • To plan and prioritise own day to day workload in line with client requirements and adapt this where necessary in line with client needs and expectations.
  • To assist in preparation of technical documentation within the Department, as required.
  • To assist in training of others, as required.
  • To ensure that all work carried out complies with departmental procedures and is cGMP compliant
  • To ensure that all personal lead times are complied with, subject to the absence of attenuating circumstances.
  • To assist in the performance of project work within the team, as required.
  • To review analytical and laboratory data within the team for accuracy, completeness and compliance with documented procedures.
  • To communicate effectively with others on site and to assist with departmental problem solving as required.
  • To ensure that all health and safety procedures are adhered to with respect to personal duties and the duties of others.
  • To undertake other laboratory and business related tasks as and when required to meet department and business needs and within the scope of the job-holder’s capabilities and responsibilities.
  • To undertake such tasks and to manage specific internal or ad hoc projects as and when required to meet department and business needs and within the scope of the job-holder’s capabilities and responsibilities.
  • Self-motivated to gain additional pharmaceutical Development Knowledge.
  • Actively seeks and demonstrates to perform tasks for the department outside of set analysis activities.
Desired Qualifications
  • Self-motivated to gain additional pharmaceutical Development Knowledge.
  • Actively seeks and demonstrates to perform tasks for the department outside of set analysis activities.

PCI Pharma Services offers end-to-end pharmaceutical packaging and related services, including Folding Cartons, Labels, Contract Packaging, Clinical Services, and Brand Protection. It serves as a one-stop source for healthcare product developers and manufacturers, handling carton and label production, packaging operations, clinical services, and brand protection under one roof. The company stands out with eight decades of experience, strict cGMP and ISO compliance, lean manufacturing, ongoing R&D, and comprehensive employee training, security, hygiene, and inspection practices. Its goal is to be a trusted, end-to-end packaging partner that delivers reliable, compliant, and scalable packaging solutions, so clients can focus on their core business.

Company Size

1-10

Company Stage

Debt Financing

Total Funding

$4B

Headquarters

Burlington, Canada

Founded

1971

Simplify Jobs

Simplify's Take

What believers are saying

  • GLP-1 surge drives demand for PCI's prefilled syringes and autoinjectors.
  • Oncology-CNS pipelines favor PCI's patient-centric drug-device combinations.
  • Bain Capital's $10B valuation fuels $1B capacity expansions through 2028.

What critics are saying

  • San Diego isolator line delays to H1 2028 cede contracts to Lonza.
  • Novo Nordisk's Catalent acquisition slashes external CDMO fill-finish availability.
  • PE backers force divestitures if biotech funding dries post-2025.

What makes PCI Pharma Services unique

  • PCI integrates sterile fill-finish with drug-device assembly for end-to-end injectables.
  • Ajinomoto Althea acquisition adds rare US high-potent ADC sterile filling expertise.
  • AVI systems inspect 75 million vials annually, scaling quality without bottlenecks.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Company News

BioProcess International
Aug 15th, 2025
Building a better facility: BPI tours PCI manufacturing plant in Bedford

On the last day of June 2025's BIO conference in Boston, Massachusetts, contract development and manufacturing organization (CDMO) PCI Pharma Services bused a crowd of delegates to its manufacturing site in Bedford, New Hampshire where it hosted a tour of its 50,000 square-foot expansion.

Montgomery County
Jul 24th, 2025
PCI Pharma Services Valued at $10B

PCI Pharma Services in Northeast Philadelphia has received a multibillion-dollar investment from Bain Capital and Kohlberg, valuing the company at $10 billion. Kohlberg had previously invested in PCI, while Bain is a new investor. The investment will help PCI expand its services and geographic reach. The company currently operates 38 sites across seven countries and employs over 7,500 people.

JD Supra
Jul 16th, 2025
Healthcare & Life Sciences Private Equity Deal Tracker: Bain Capital and Kohlberg Invest in PCI Pharma

Healthcare & life sciences Private Equity deal tracker: Bain Capital and Kohlberg invest in PCI Pharma.

FinSMEs
Jul 15th, 2025
PCI Pharma Services Receives Investment from Mubadala, Bain Capital, and Kohlberg

PCI Pharma, a Philadelphia, PA-based contract development and manufacturing organization (CDMO) focused on biotherapies, received an investment from Bain Capital, Kohlberg, and Mubadala Investment Company.

MarketScreener
Jul 14th, 2025
PCI Pharma Services receives new funding

PCI Pharma Services announced it received a new round of funding on July 14, 2025. The funding was co-led by new investor Bain Capital, LP, and returning investor Kohlberg & Company, L.L.C. Additional participation came from returning investors Mubadala Investment Company PJSC and Partners Group Holding AG.

INACTIVE